Zevra director granted 30,000 stock options

Q: What is the exercise price of Corey Watton’s ZVRA stock options?

The stock options have an exercise price of $11.17 per share, equal to the Nasdaq Global Select Market closing price of Zevra’s common stock on June 4, 2026, the date the options were granted.

Q: When do the ZVRA stock options granted to Corey Watton expire?

The options granted to Corey Michael Watton expire on June 3, 2036. After this expiration date, any unexercised options will no longer be usable to purchase Zevra Therapeutics common shares at the specified exercise price.

Q: Is Corey Watton’s ZVRA option grant an open-market purchase or compensation?

The 30,000-share option grant is compensation for service on Zevra’s board, not an open-market stock purchase. It was awarded under the company’s tenth amended and restated non-employee director compensation policy.

Q: How many Zevra options does Corey Watton hold after this grant?

After this transaction, Corey Michael Watton holds 30,000 stock options directly, all from this single grant, giving him the right to acquire up to 30,000 Zevra common shares if the options vest and are exercised.

Zevra Therapeutics director Corey Michael Watton received a grant of stock options for 30,000 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zevra Therapeutics director Corey Michael Watton received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $11.17 per share, matching the June 4, 2026 Nasdaq closing price, and expire on June 3, 2036.

This award was granted as compensation for his service on the board under Zevra’s non-employee director compensation policy, not through open-market buying. All 30,000 options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, assuming continued board service.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Watton Corey Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct)

Footnotes (3)

F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
F2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 30,000 options Exercise price: $11.17 per share Underlying shares: 30,000 shares +3 more

6 metrics

Option grant size 30,000 options Stock Option (right to buy) granted June 4, 2026

Exercise price $11.17 per share Equal to Nasdaq closing price on June 4, 2026

Underlying shares 30,000 shares Common stock underlying the options

Post-transaction derivative holdings 30,000 options Total options held directly after grant

Expiration date June 3, 2036 Option term end date

Vesting 100% cliff vesting Earlier of 1-year anniversary, pre-annual meeting, or pre-change in control

Key Terms

Stock Option (right to buy), non-employee director compensation policy, change in control, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

non-employee director compensation policy financial

"awarded as compensation pursuant to the Issuer's tenth amended and restated non-employee director compensation policy"

change in control financial

"immediately prior to a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vesting financial

"One hundred percent (100%) of the shares subject to the option shall vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ZEVRA director Corey Michael Watton receive in this Form 4 filing?

Corey Michael Watton received a grant of stock options for 30,000 shares of Zevra Therapeutics common stock as board compensation, giving him the right to buy shares at a fixed exercise price if vesting conditions are satisfied.

What is the exercise price of Corey Watton’s ZVRA stock options?

The stock options have an exercise price of $11.17 per share, equal to the Nasdaq Global Select Market closing price of Zevra’s common stock on June 4, 2026, the date the options were granted.

When do Corey Watton’s ZVRA stock options vest?

One hundred percent of the 30,000 options vest on the earlier of the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to his continued board service.

When do the ZVRA stock options granted to Corey Watton expire?

The options granted to Corey Michael Watton expire on June 3, 2036. After this expiration date, any unexercised options will no longer be usable to purchase Zevra Therapeutics common shares at the specified exercise price.

Is Corey Watton’s ZVRA option grant an open-market purchase or compensation?

The 30,000-share option grant is compensation for service on Zevra’s board, not an open-market stock purchase. It was awarded under the company’s tenth amended and restated non-employee director compensation policy.

How many Zevra options does Corey Watton hold after this grant?

After this transaction, Corey Michael Watton holds 30,000 stock options directly, all from this single grant, giving him the right to acquire up to 30,000 Zevra common shares if the options vest and are exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 04:16 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watton Corey Michael

(Last)

(First)

(Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$11.17⁽¹⁾	06/04/2026		A		30,000⁽²⁾		⁽³⁾	06/03/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Corey M. Watton	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR